Adverse event consortium links with UCSD on genetics of drug-induced renal injury
This article was originally published in Scrip
The International Serious Adverse Events Consortium (iSAEC) is collaborating with the University of California, San Diego's School of Medicine and UCSD's Skaggs School of Pharmacy to research the genetics of drug-induced renal injury (DIRI).
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.